The goal of the project is to create a feasible model for assessing the condition of bone turnover in diabetic patients and to assess the clinical utility of the model in detecting diabetic osteopathy. The Endocrinology Department of the Therapeutic Clinic at AM University was the site of the study from 2015 to 2017. 235 patients in all were evaluated for the study (98 with T1DM and 137 with T2DM). 89 healthy individuals served as controls. All 235 patients had their bone mineral density (BMD) assessed using dual energy X-ray absorptiometry (DXA), along with parathyrin, 25(OH) D, and serum levels of the markers of bone remodelling amino terminal propeptide of procollagen type I (P1NP) and c-terminal telopeptide of type I collagen (CTX). Our findings demonstrate that independent of age or disease duration, individuals with T2DM had lower b-CTx values and significantly greater levels of P1NP, implying less dramatic changes in bone metabolism compared to those with T1DM. Compared to 13% of patients with T2DM, osteoporosis was found in 50% of T1DM patients. When assessing the condition of bone tissue in the early stages of diabetes, bone remodelling markers can be helpful because changes in bone microarchitecture may not always be picked up by tests of bone mineral density.
